Future Science Group

Feb 19 2025 288 ep. 16 mins 384

Future Science Group Podcast artwork

Podcast by Taylor & Francis Group

Copy RSS

Subscribe on Podcast Addict

Cell therapies for autoimmune diseases: a podcast with Lindsay Davies

Feb 19 2025 13 mins

This International Women’s Day, we’re joined by Lindsay Davies, Chief Scientific Officer at NextCell Pharma (Stockholm, Sweden), to discuss the evolving role of cell therapies in treating autoimmune diseases. In this podcast, Davies breaks down the science behind NextCell’s mesenchymal stromal cell therapy for type 1 diabetes and explores how these cells could be applied to

The use of GenAI in bioanalysis: an interview with Priyata Kalra

Feb 06 2025 28 mins

During the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 2024 conference, Bioanalysis Zone caught up with industry experts across numerous disciplines to discuss their involvement with AAPS and their research. In this interview, we spoke to Priyata Kalra about her talk on the use of GenAI within biomedicine.

The need for HRMS for quantitation of ADCs vs. QQQ: an interview with Megan Cooley

Jan 09 2025 21 mins

In this episode, we sit down with Megan Cooley, Associate Director of Bioanalytical Services at ICON (KS, USA), to explore the cutting-edge world of antibody-drug conjugate (ADC) quantitation using high-resolution mass spectrometry (HRMS). Megan delves into the capabilities of Triple Quadrupole and Time-of-Flight mass spectrometry, offering her expert insights into whether HRMS is

How can medical device regulation catch up with innovation?

Dec 16 2024 12 mins

In this interview, we discuss the potential of AI in increasing healthcare system efficiency, how medical devices are making procedures less invasive and what those working in the field of medical devices can do to help regulation catch up with innovation.

The new frontier: assessing efficacy and safety of CGTs using biomarkers

Sep 27 2024 24 mins

In the sixth episode of The new frontier podcast, we're joined by Catherine Vrentas, Life Sciences Lead at Booz Allen Hamilton (VA, USA). Cathy explains how biomarkers can be used to predict the therapeutic outcome and efficacy of CGTs and the biomarkers in particular that have shown strong predictive value. We delve into the common challenges of working with biomarkers in CGTs and

Carlon Fitzpatrick AI Summit

Sep 11 2024 3 mins

Carlon Fitzpatrick AI Summit by Taylor & Francis Group

Challenges and solutions in monitoring assay performance for vaccine development

Jul 31 2024 18 mins

Challenges and solutions in monitoring assay performance for vaccine development: an interview with Atul Chaudhari

ADA detection and characterization for immunogenicity testing: insights from ICON's Lindsay Denhoff

Jul 09 2024 11 mins

We caught up with Principal Scientist Lindsay Denhoff (ICON; Dublin, Ireland) to discuss immunogenicity considerations for therapeutic proteins and the current analytical methodologies for detecting and characterizing anti-drug antibodies (ADAs). Lindsay shares some industry best practices for achieving high-quality ADA assays, as well as some of the advantages and limitations of s

Tech Blast | Epitope binning

May 16 2024 19 mins

In this Tech Blast episode supported by Sartorius (Göttingen, Germany), we speak with David Apiyo – Manager of Applications Development at Sartorius (MN, USA) – about epitope binning, why it's performed and the best ways to conduct it. Plus, learn more about Sartorius' biolayer interferometry platforms and their application in epitope binning.

Using the Gyrolab® platform for oligo quantification: an interview with John Chappell

Apr 30 2024 6 mins

In this interview, we spoke to John Chappell, Senior Global Scientific Support Manager at Gyros Protein Technologies (Uppsala, Sweden) about his experience working with the Gyrolab platform for oligonucleotide assays. John discusses the advantages of using Gyrolab for oligo quantification in biological fluids and shares his thoughts on the next steps for these assays.